Everything below concerns Thymalfasin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-31. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Valence 3 is dominant in all subsequent elements up to lawrencium (with the exception of nobelium). Curium can be tetravalent in solids (fluoride, dioxide). Berkelium, along with a valence of +3, also shows the valence of +4, more stable than that of curium; the valence 4 is observed in solid fluoride and dioxide. The stability of Bk4+ in aqueous solution is close to that of Ce4+. Only valence 3 was observed for californium, einsteinium and fermium. The divalent state is proven for mendelevium and nobelium, and in nobelium it is more stable than the trivalent state. Lawrencium shows valence 3 both in solutions and solids. The redox potential
== Medical uses == Glibenclamide is used to lower the blood sugar level in patients with type 2 diabetes mellitus, which is not controlled by diet and exercise alone. It is not as good as either metformin or insulin in those who have gestational diabetes.
== Statements by Combatants' Presidents and Prime ministers == On 7 August, state-controlled Rossiya TV aired Abkhaz separatist leader Sergei Bagapsh, who said at a meeting of the Abkhaz National Security Council: "I have spoken to the president of South Ossetia. It has more or less stabilized now. A battalion from the North Caucasus District has entered the area." The phone conversation between Bagapsh and Kokoity had taken place on late 6 August. By the evening of 7 August, Bagapsh had ordered the Abkhaz armed forces to raise combat readiness. Pro-Georgian president of South Ossetia Dmitry Sanakoyev told Russian journalist Dmitry Steshin by 8 August 2008 that neither he nor the Georgian government needed the war and cited multi-billion Georgian investment into the development of South Ossetia as a proof that Georgia was not preparing the war. Prime Minister Lado Gurgenidze said on 8 August that South Ossetian separatists launched a deliberate attack on the Georgian civilians after Saakashvili's announcement of ceasefire and that 100-vehicle armed convoy had entered through the Roki Tunnel from Russia before the midnight. Gurgenidze said that the Georgian government had notified the command of the Russian peacekeepers that Georgia was forced to respond to the attack. On 11 August 2008, Georgian president Mikheil Saakashvili wrote that the war was provoked by the Kremlin and while Georgia was showing restraint, Russia escalated the conflict in South Ossetia.
=== Government regulations === The World Health Organization (WHO), the specialized agency of the United Nations (UN) that is concerned with international public health, published Quality control methods for medicinal plant materials in 1998 to support WHO Member States in establishing quality standards and specifications for herbal materials, within the overall context of quality assurance and control of herbal medicines. In the European Union (EU), herbal medicines are regulated under the Committee on Herbal Medicinal Products. In the United States, herbal remedies are regulated dietary supplements by the Food and Drug Administration (FDA) under current good manufacturing practice (cGMP) policy for dietary supplements. Manufacturers of products falling into this category are not required to prove the safety or efficacy of their product so long as they do not make 'medical' claims or imply uses other than as a 'dietary supplement', though the FDA may withdraw a product from sale should it prove harmful. Canadian regulations are described by the Natural and Non-prescription Health Products Directorate which requires an eight-digit Natural Product Number or Homeopathic Medicine Number on the label of licensed herbal medicines or dietary supplements. Some herbs, such as cannabis and coca, are outright banned in most countries though coca is legal in most of the South American countries where it is grown. The Cannabis plant is used as a herbal medicine, and as such is legal in some parts of the world.
Sources: en.wikipedia.org
== SB == Sb – (s) Antimony (Latin Stibium) SbA - Stibarsen, an alloy of antimony and arsenic SB (i) Sexy Bitch Sexy Bastard Sexy Boy (disambiguation) (s) Solomon Islands (ISO 3166 digram) (i) Special Warfare Boat Operator SBA (i) Santa Barbara Airport Simulation-Based Acquisition Small Business Administration Sovereign Base Area Student bar association SBB – (i) German for the Swiss Federal Railways SBC (i) Sensotronic Brake Control Single-Board Computer Southern Baptist Convention Sun Belt Conference (US college sports) SBCCOM – (p) U.S. Army Soldier and Biological Chemical Command (disbanded 2003) SBCS – (i) Single-Byte Character Set SBCT – (i) Stryker Brigade Combat Team SBD (s) Solomon Islands dollar (ISO 4217 currency code) Silent But Deadly SBP (i) Samahang Basketbol ng Pilipinas (Filipino, "Basketball Federation of the Philippines") U.S. School Breakfast Program Society of Business Practitioners State Bank of Pakistan SBS (i) Special Boat Service Special Broadcasting Service Seoul Broadcasting System SBW (i) Sonny Bill Williams (New Zealand dual-code rugby player)
For a definitive diagnosis to be made, symptoms must occur within 6 hours of transfusion, hypoxemia must be present, there must be radiographic evidence of bilateral infiltrates and there must be no evidence of left atrial hypertension (fluid overload). It occurs in 15% of the transfused patient with mortality rate of 5 to 10%. Recipient risk factors includes: end-stage liver disease, sepsis, haematological malignancies, sepsis, and ventilated patients. Antibodies to human neutrophil antigens (HNA) and human leukocyte antigens (HLA) have been associated with this type of transfusion reaction. Donor's antibodies interacting with antigen positive recipient tissue result in release of inflammatory cytokines, resulting in pulmonary capillary leakage. The treatment is supportive. Transfusion associated circulatory overload (TACO) is a common, yet underdiagnosed, reaction to blood product transfusion consisting of the new onset or exacerbation of three of the following within 6 hours of cessation of transfusion: acute respiratory distress, elevated brain natriuretic peptide (BNP), elevated central venous pressure (CVP), evidence of left heart failure, evidence of positive fluid balance, and/or radiographic evidence of pulmonary vascular congestion. Patients with congestive heart failure or kidney disease are more susceptible to volume overload. For especially vulnerable patients, a standard RBC unit could be split by sterile technique in the blood bank and administered over 8 hours instead of the standard 4 hours.
==== Intracrine function of VEGF in cardiac cells ==== VEGF has been identified as an intracrine factor, meaning that it not only acts through autocrine and paracrine pathways but also functions within the cells that produce it. In cardiac myocytes and endothelial cells, VEGF can be synthesized and retained intracellularly, where it directly influences gene expression, protein synthesis, and cellular survival mechanisms. Unlike its secreted counterpart, intracrine VEGF operates independently of cell-surface receptors, exerting effects within the nucleus and cytoplasm. Studies suggest that intracrine VEGF contributes to cellular differentiation during cardiac organogenesis. In embryonic and progenitor cardiac cells, VEGF facilitates the transcription of genes involved in cell survival, proliferation, and vascular patterning. Its presence in stem cell nuclei suggests that it may regulate ribosomal DNA transcription, similar to other intracrines, thereby coordinating cellular growth and differentiation.
== Release details == 1907, France, L'illustration, Pub September–November 1907, magazine serial (in French) 1908, France, Editions Jacques Lafitte (ISBN NA), (First edition) (in French) 1934, UK, Oxford University Press ISBN 0-19-832345-X, (in French) 1977, UK, Dover Publications ISBN 0-486-23460-6 1978, UK, Remploy ISBN 0-7066-0759-7 1996, US, Books on Tape ISBN 5-557-12771-2 1996, US, Buccaneer Books ISBN 0-89966-141-6 1997, UK, Dedalus Ltd ISBN 1-873982-38-0 2002, US, Indypublish.com ISBN 1-4043-2003-2 2002, US, Indypublish.com ISBN 1-4043-2002-4 2004, UK, Thorndike Press ISBN 0-7862-6991-X 2005, US, Kessinger Publishing ISBN 0-7661-9366-7 2006, UK, Blackstone Audiobooks ISBN 0-7861-7523-0, audio book (MP3 CD) 2006, UK, Dover Publications ISBN 0-486-44928-9 2009, US, Black Coat Press ISBN 1-934543-60-8
Pattern hair loss, also known as androgenetic alopecia, is a hair loss condition that primarily affects the top and front of the scalp. In male-pattern hair loss, the hair loss typically presents itself as either a receding front hairline, loss of hair on the crown and vertex of the scalp, or a combination of both. Female-pattern hair loss typically presents as a diffuse thinning of the hair across the entire scalp. The condition is caused by a combination of male sex hormones and genetic factors. Some research has found evidence for the role of oxidative stress in hair loss, the microbiome of the scalp, genetics, and circulating androgens; particularly dihydrotestosterone. Men with early onset androgenic alopecia (before the age of 35) have been deemed the male phenotypic equivalent for polyendocrine metabolic ovarian syndrome. The cause of female pattern hair loss remains unclear; androgenetic alopecia for women is associated with an increased risk of polyendocrine metabolic ovarian syndrome. Management of hair loss may include styling the remaining hair in a creative manner to make hair loss less apparent or shaving one's head to improve the aesthetic aspect of the condition. Otherwise, common medical treatments include platelet-rich plasma, low-level laser therapy, minoxidil, finasteride, dutasteride, or hair transplant surgery. Use of finasteride and dutasteride in women is not well-studied and may result in birth defects if taken during pregnancy. By the age of 50, pattern hair loss affects about half of males and a quarter of females.
Sources: en.wikipedia.org
To make new legislation, TFEU article 294 defines the "ordinary legislative procedure" that applies for most EU acts. The essence is there are three readings, starting with a Commission proposal, where the Parliament must vote by a majority of all MEPs (not just those present) to block or suggest changes, and the Council must vote by qualified majority to approve changes, but by unanimity to block Commission amendment. Where the different institutions cannot agree at any stage, a "Conciliation Committee" is convened, representing MEPs, ministers and the commission to try to get agreement on a joint text: if this works, it will be sent back to the Parliament and Council to approve by absolute and qualified majority. This means, legislation can be blocked by a majority in Parliament, a minority in the council, and a majority in the commission: it is harder to change EU law than for it to stay the same. A different procedure exists for budgets. For "enhanced cooperation" among a sub-set of at least member states, authorisation must be given by the council. Member state governments should be informed by the Commission at the outset before any proposals start the legislative procedure. The EU as a whole can only act within its power set out in the Treaties. TEU articles 4 and 5 state that powers remain with the member states unless they have been conferred, although there is a debate about the Kompetenz-Kompetenz question: who ultimately has the "competence" to define the EU's "competence".
A theory a one level of generality cannot answer questions about matters at a different level of generality." Walt's balance of threat formulation allows neorealism to serve as the foundation for a theory of foreign policy, thus allowing it to explain or predict which potential threats a state is most likely to balance against.
People with persistent symptoms after appropriate treatments are said to have post-treatment Lyme disease syndrome (PTLDS). Prevention includes efforts to prevent tick bites by wearing clothing to cover the arms and legs and using DEET or picaridin-based insect repellents. As of 2026, clinical trials of proposed human vaccines for Lyme disease are being carried out and one is up for regulatory approval, but no vaccine is available. A vaccine, LYMERix, was produced but discontinued in 2002 due to insufficient demand. Several vaccines prevent Lyme disease in dogs.
=== Reporting dates === Several formats for citing radiocarbon results have been used since the first samples were dated. As of 2019, the standard format required by the journal Radiocarbon is as follows. Uncalibrated dates should be reported as "laboratory:
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.